Ad is loading...
ABVCX
Price
$20.49
Change
+$0.15 (+0.74%)
Updated
Nov 22 closing price
VVIAX
Price
$70.26
Change
+$0.54 (+0.77%)
Updated
Nov 22 closing price
Ad is loading...

ABVCX vs VVIAX

Header iconABVCX vs VVIAX Comparison
Open Charts ABVCX vs VVIAXBanner chart's image
AB Large Cap Value C
Price$20.49
Change+$0.15 (+0.74%)
VolumeN/A
CapitalizationN/A
Vanguard Value Index Adm
Price$70.26
Change+$0.54 (+0.77%)
VolumeN/A
CapitalizationN/A
ABVCX vs VVIAX Comparison Chart
Loading...
View a ticker or compare two or three
VS
ABVCX vs. VVIAX commentary
Nov 23, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABVCX is a StrongBuy and VVIAX is a StrongBuy.

FUNDAMENTALS
Fundamentals
VVIAX has more cash in the bank: 184B vs. ABVCX (472M). VVIAX pays higher dividends than ABVCX: VVIAX (2.36) vs ABVCX (0.15). ABVCX was incepted earlier than VVIAX: ABVCX (24 years) vs VVIAX (24 years). ABVCX is a more actively managed with annual turnover of: 45.00 vs. VVIAX (10.00). ABVCX has a lower initial minimum investment than VVIAX: ABVCX (2500) vs VVIAX (3000). VVIAX (26.09) and ABVCX (25.54) have marching annual gain over last year. VVIAX return over 5 years is better than : 53.09 vs. ABVCX (37.02).
ABVCXVVIAXABVCX / VVIAX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence24 years24 years-
Gain YTD23.06319.672117%
Front LoadN/AN/A-
Min. Initial Investment2500300083%
Min. Initial Investment IRAN/AN/A-
Net Assets472M184B0%
Annual Yield % from dividends0.152.366%
Returns for 1 year25.5426.0998%
Returns for 3 years6.3724.7726%
Returns for 5 years37.0253.0970%
Returns for 10 years45.08112.2640%
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
DOLE15.260.19
+1.26%
Dole plc
NCNO40.450.37
+0.92%
nCino
SGHT3.760.03
+0.80%
Sight Sciences
VICI32.370.25
+0.78%
VICI Properties
SABS3.070.01
+0.33%
SAB Biotherapeutics